CN101932938B - 作为标记物用于化学疗法的tle3 - Google Patents
作为标记物用于化学疗法的tle3 Download PDFInfo
- Publication number
- CN101932938B CN101932938B CN200880125991.9A CN200880125991A CN101932938B CN 101932938 B CN101932938 B CN 101932938B CN 200880125991 A CN200880125991 A CN 200880125991A CN 101932938 B CN101932938 B CN 101932938B
- Authority
- CN
- China
- Prior art keywords
- cancer
- tle3
- patient
- purposes
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99148707P | 2007-11-30 | 2007-11-30 | |
US60/991,487 | 2007-11-30 | ||
PCT/US2008/084685 WO2009073478A2 (en) | 2007-11-30 | 2008-11-25 | Tle3 as a marker for chemotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101932938A CN101932938A (zh) | 2010-12-29 |
CN101932938B true CN101932938B (zh) | 2014-08-27 |
Family
ID=40718444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880125991.9A Expired - Fee Related CN101932938B (zh) | 2007-11-30 | 2008-11-25 | 作为标记物用于化学疗法的tle3 |
Country Status (8)
Country | Link |
---|---|
US (5) | US7816084B2 (zh) |
EP (1) | EP2227693B1 (zh) |
JP (1) | JP5745273B2 (zh) |
CN (1) | CN101932938B (zh) |
CA (1) | CA2706881A1 (zh) |
GB (1) | GB2460769C (zh) |
HK (1) | HK1152563A1 (zh) |
WO (1) | WO2009073478A2 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137187A2 (en) | 2006-05-18 | 2007-11-29 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
US7816084B2 (en) * | 2007-11-30 | 2010-10-19 | Applied Genomics, Inc. | TLE3 as a marker for chemotherapy |
WO2010045318A2 (en) * | 2008-10-14 | 2010-04-22 | Caris Mpi, Inc. | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type |
GB2463401B (en) | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
US20110166030A1 (en) * | 2009-09-30 | 2011-07-07 | Yixin Wang | Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells |
CA2791905A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarkers for theranostics |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
KR101976219B1 (ko) * | 2011-04-15 | 2019-05-07 | 제이 파마 가부시끼가이샤 | 유방암의 바이오마커 |
CA2876199A1 (en) * | 2012-06-13 | 2013-12-19 | University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group | Compositions and methods for treating cancer |
CN102749448B (zh) * | 2012-07-27 | 2014-07-02 | 复旦大学附属中山医院 | 用于评估肺腺癌化疗效果的试剂盒 |
EP3210144B1 (en) | 2014-10-24 | 2020-10-21 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
ES2857953T3 (es) | 2014-10-24 | 2021-09-29 | Koninklijke Philips Nv | Pronóstico médico y predicción de la respuesta al tratamiento usando las actividades de múltiples rutas de señalización celular |
DK3210142T3 (da) | 2014-10-24 | 2020-11-16 | Koninklijke Philips Nv | Vurdering af tgf-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression |
CN107548498A (zh) | 2015-01-20 | 2018-01-05 | 南托米克斯有限责任公司 | 用于反应预测高级别膀胱癌中的化疗的系统和方法 |
AU2016309659A1 (en) | 2015-08-14 | 2018-04-12 | Koninklijke Philips N.V. | Assessment of NFkB cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3387443A4 (en) * | 2015-12-10 | 2019-11-13 | Nantomics, LLC | INTEGRATED ANALYSIS TO DETERMINE PROGNOSIS AFTER THE TREATMENT OF PRIMARY BREAST CANCER |
EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007046823A2 (en) * | 2004-11-30 | 2007-04-26 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5168393A (en) * | 1992-09-30 | 1994-04-26 | Yale University | Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids |
AU5168193A (en) | 1992-09-30 | 1994-04-26 | Medical Research Council | Human homologs of the transducin-like enhancer of split gene and methods based thereon |
US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
CN1054382C (zh) * | 1996-03-05 | 2000-07-12 | 核工业北京化工冶金研究院 | 用反相制备液相色谱法分离纯化紫杉醇的方法 |
WO2000052204A2 (en) * | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
WO2002040716A2 (en) * | 2000-11-16 | 2002-05-23 | Cemines, Llc | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
US20040072154A1 (en) | 2000-12-22 | 2004-04-15 | Morris David W. | Novel compositions and methods for cancer |
US7820447B2 (en) * | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
US20040029114A1 (en) * | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
ITMI20011734A1 (it) * | 2001-08-07 | 2003-02-07 | Indena Spa | Derivanti tassanici e procedimenti per la loro preparazione |
US20070237770A1 (en) * | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
US20040002067A1 (en) | 2001-12-21 | 2004-01-01 | Erlander Mark G. | Breast cancer progression signatures |
US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
US20030216758A1 (en) * | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
US20040253606A1 (en) * | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
CA2508348C (en) | 2002-12-06 | 2016-07-12 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
US20040156884A1 (en) * | 2003-02-10 | 2004-08-12 | Brown Dale G. | Emulsion impregnated rawhide chews with antimicrobially active chlorhexidine |
EP1608255A4 (en) | 2003-04-01 | 2008-06-25 | Univ Johns Hopkins Med | MODELS FOR THE EXPRESSION OF MAMMARY ENDOTHELIAL CELLS |
JP2007506135A (ja) * | 2003-09-22 | 2007-03-15 | コニンクリユケ フィリップス エレクトロニクス エヌ.ブイ. | 必要メモリを低減された双安定ディスプレイ |
GB0323225D0 (en) | 2003-10-03 | 2003-11-05 | Ncc Technology Ventures Pte Lt | Materials and methods relating to breast cancer classification |
EP1538218A1 (en) | 2003-12-04 | 2005-06-08 | Erasmus University Medical Center Rotterdam | Method to diagnose or screen for inflammatory diseases |
JP2007519756A (ja) * | 2004-01-30 | 2007-07-19 | アンジオテック インターナショナル アーゲー | 拘縮を治療するための組成物および方法 |
US20090004173A1 (en) | 2004-05-28 | 2009-01-01 | St. Jude Children's Research Hospital | Diagnosis and Treatment of Drug Resistant Leukemia |
KR101357038B1 (ko) * | 2004-12-08 | 2014-02-03 | 아벤티스 파마슈티칼스 인크. | 도세탁셀에 대한 내성 또는 감수성을 측정하는 방법 |
BRPI0607753A2 (pt) | 2005-02-16 | 2009-10-06 | Wyeth Corp | método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml |
US7504225B2 (en) | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
MX2007014537A (es) | 2005-05-18 | 2008-02-12 | Wyeth Corp | Genes de la enfermedad de la leucemia y sus usos. |
US20070172844A1 (en) * | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
WO2007117439A2 (en) * | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
US20090105167A1 (en) * | 2007-10-19 | 2009-04-23 | Duke University | Predicting responsiveness to cancer therapeutics |
US7816084B2 (en) * | 2007-11-30 | 2010-10-19 | Applied Genomics, Inc. | TLE3 as a marker for chemotherapy |
-
2008
- 2008-11-25 US US12/277,920 patent/US7816084B2/en not_active Expired - Fee Related
- 2008-11-25 WO PCT/US2008/084685 patent/WO2009073478A2/en active Application Filing
- 2008-11-25 CA CA 2706881 patent/CA2706881A1/en not_active Abandoned
- 2008-11-25 JP JP2010536127A patent/JP5745273B2/ja not_active Expired - Fee Related
- 2008-11-25 GB GB0910374A patent/GB2460769C/en not_active Expired - Fee Related
- 2008-11-25 CN CN200880125991.9A patent/CN101932938B/zh not_active Expired - Fee Related
- 2008-11-25 EP EP08855868.9A patent/EP2227693B1/en not_active Not-in-force
-
2009
- 2009-10-13 US US12/578,255 patent/US7754431B2/en not_active Expired - Fee Related
-
2010
- 2010-09-24 US US12/889,630 patent/US9005900B2/en not_active Expired - Fee Related
-
2011
- 2011-06-15 HK HK11106089.6A patent/HK1152563A1/zh not_active IP Right Cessation
-
2012
- 2012-11-27 US US13/685,924 patent/US8785156B2/en not_active Expired - Fee Related
-
2015
- 2015-03-27 US US14/671,015 patent/US20150198599A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007046823A2 (en) * | 2004-11-30 | 2007-04-26 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
Non-Patent Citations (2)
Title |
---|
US2007237770A1A1 2007.10.11 |
WO2007046823A2A2 2007.04.26 |
Also Published As
Publication number | Publication date |
---|---|
EP2227693B1 (en) | 2015-08-19 |
HK1152563A1 (zh) | 2012-03-02 |
JP2011505562A (ja) | 2011-02-24 |
US8785156B2 (en) | 2014-07-22 |
US20150198599A1 (en) | 2015-07-16 |
US9005900B2 (en) | 2015-04-14 |
WO2009073478A2 (en) | 2009-06-11 |
CA2706881A1 (en) | 2009-06-11 |
EP2227693A2 (en) | 2010-09-15 |
US20130079392A1 (en) | 2013-03-28 |
WO2009073478A9 (en) | 2009-12-23 |
US20110015259A1 (en) | 2011-01-20 |
GB0910374D0 (en) | 2009-07-29 |
CN101932938A (zh) | 2010-12-29 |
US7754431B2 (en) | 2010-07-13 |
WO2009073478A3 (en) | 2009-08-27 |
US20100062444A1 (en) | 2010-03-11 |
GB2460769C (en) | 2011-09-07 |
US7816084B2 (en) | 2010-10-19 |
GB2460769A (en) | 2009-12-16 |
EP2227693A4 (en) | 2011-05-04 |
US20090155798A1 (en) | 2009-06-18 |
GB2460769B (en) | 2010-06-02 |
JP5745273B2 (ja) | 2015-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101932938B (zh) | 作为标记物用于化学疗法的tle3 | |
JP6983746B2 (ja) | 葉酸受容体1の検出用の抗体及びアッセイ | |
ES2351938T3 (es) | Reactivos y métodos para su uso en el diagnóstico, clasificación y terapia del cáncer . | |
Malempati et al. | Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group | |
KR101393144B1 (ko) | 요로상피암의 검출용 키트 및 방법 | |
CN106461681B (zh) | 用于诊断血管疾病的生物标志物及其用途 | |
AU2011281706A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
JP2013522167A (ja) | uPAR結合剤及びその使用方法 | |
Goldstein et al. | Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer | |
CA2983126A1 (en) | Methods for treating lung cancer | |
US9739781B2 (en) | Anti-phospho-Akt antibodies | |
WO2000035950A9 (en) | Reagents and methods useful for detecting diseases of the breast | |
JP2015108639A (ja) | タキサン型化学療法剤用のインジケータとしてのser473でのaktリン酸化反応 | |
Kaira et al. | Evaluation of thoracic tumors with 18F‐FMT and 18F‐FDG PET‐CT: a clinicopathological study | |
US20040265932A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
WO2005017530A1 (en) | Reagents and methods for use in cancer diagnosis, classification and therapy | |
US20050048588A1 (en) | Immunogenic cancer peptides and uses thereof | |
TW202204639A (zh) | Rbm10基因的用途 | |
US6552164B1 (en) | Reagents and methods useful for detecting diseases of the breast | |
EP3690051A1 (en) | Anti-ckap4 monoclonal antibody | |
CN107589262B (zh) | 用于检测乳腺癌的试剂盒 | |
Kubala | The Role of NADH Dehydrogenase [Ubiquinone] 1 Alpha Subcomplex 4-Like-2 in Clear Cell Renal Cell Carcinoma | |
US20100143947A1 (en) | Reagents and methods for use in cancer diagnosis, classification and therapy | |
CN116813778A (zh) | 一种靶向中期因子mdk的d4纳米抗体及其衍生物和应用 | |
Goldstein | Development of the G3 Designed ankyrin repeat protein (DARPin) for HER2 imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1152563 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: KRET DIAGNOSIS AND TREATMENT SERVICE COMPANY Free format text: FORMER OWNER: APPLIED GENOMICS, INC. Effective date: 20120907 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120907 Address after: American California Applicant after: Kret Diagnosis and Treatment Service Company Address before: American California Applicant before: Applied Genomics Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1152563 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20161125 |